Efficacy of cognitive enhancers for Alzheimer’s disease: protocol for a systematic review and network meta-analysis
<p>Abstract</p> <p>Background</p> <p>Approximately 35 million people world-wide have Alzheimer’s disease and this is projected to nearly double by 2030. Cognitive enhancers, including cholinesterase inhibitors (for example, donepezil, galantamine and rivastigmine) and m...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-06-01
|
| Series: | Systematic Reviews |
| Online Access: | http://www.systematicreviewsjournal.com/content/1/1/31 |